Cross-species research shows that RNA splicing patterns, not just gene activity, track maximum lifespan in mammals, revealing ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...

This strategic partnership with WuXi XDC represents a major milestone for Akari and a powerful validation of our novel PH1 payload technology,” said Abizer Gaslightwala, President and Chief Executive ...

Scientists have launched the £1.5 million study at the University of Edinburgh’s Institute of Genetics and Cancer (IGC). It aims to disrupt cancer’s DNA messaging system, which allows cancer cells to ...

Paving way for new therapies, researchers decode how parasites that spread one of the world's deadliest diseases use trickery ...

Researchers led by Davide Incarnato at the University of Groningen have demonstrated that the FDA-approved cancer drug ...

PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National ...

PepGen Inc. PEPG shares are down during Tuesday’s premarket session following the announcement of topline results from the ...

Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March ...

Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global population infected with ...